Modifications of the Immune Responsiveness in Patients with Hepatitis C Virus Infection following Treatment with IFN-α / Ribavirin

Author(s): L. Amati, L. Caradonna, T. Magrone, M. L. Mastronardi, R. Cuppone, R. Cozzolongo, O. G. Manghisi, D. Caccavo, A. Amoroso, E. Jirillo.

Journal Name: Current Pharmaceutical Design

Volume 8 , Issue 11 , 2002

Become EABM
Become Reviewer

Abstract:

The balance between T helper (h)1 and Th2 responsiveness seems to represent a key event in the evolution of hepatitis C virus (HCV) infection. In particular, Th1 cytokines [interleukin (IL-2) and interferon (IFN-γ)] have been demonstrated to mediate the antiviral immune response. Serum levels of Th1 cytokines (IL-2 and IFN-γ) as well as of Th2 products (IL-4 and IL-10) were determined in a group of HCV-positive patients before and after treatment with IFN-α and Ribavirin (RIB). Results indicate that responder patients exhibited increased levels of IFN-γ and IL-10, while this enhancement was not observed in non-responder patients. In this respect, the major effect exerted by the combined therapy with IFN-α / RIB could be represented by the attainment of a re-equilibrium between inflammatory (Th1) and antiinflammatory (Th2) mechanisms. In this framework, according to current literature, novel therapeutical approaches to treat HCV infection are represented by administration of recombinant IL-2 and IL-10.

Keywords: ifn, ribavirin, responsiveness, gamma, interleukin, recombinant interleukin

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 8
ISSUE: 11
Year: 2002
Page: [981 - 993]
Pages: 13
DOI: 10.2174/1381612024607036
Price: $58

Article Metrics

PDF: 3